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Neuropathy is one of the most debilitating complications
of both type 1 and type 2 diabetes, with estimates of preva-
lence between 50–90% depending on the means of detec-
tion. Diabetic neuropathies are heterogeneous and there is
variable involvement of large myelinated ﬁbers and small,
thinly myelinated ﬁbers. Many of the neuronal abnormal-
ities in diabetes can be duplicated by experimental deple-
tionofspeciﬁcneurotrophicfactors,theirreceptorsortheir
binding proteins. In experimental models of diabetes there
is a reduction in the availability of these growth factors,
which may be a consequence of metabolic abnormalities,
or may be independent of glycemic control. These neu-
rotrophic factors are required for the maintenance of the
neurons, the ability to resist apoptosis and regenerative ca-
pacity. The best studied of the neurotrophic factors is nerve
growth factor (NGF) and the related members of the neu-
rotrophin family of peptides. There is increasing evidence
that there is a deﬁciency of NGF in diabetes, as well as the
dependent neuropeptides substance P (SP) and calcitonin
gene-related peptide (CGRP) that may also contribute to
the clinical symptoms resulting from small ﬁber dysfunc-
tion. Similarly, NT3 appears to be important for large ﬁber
andIGFsforautonomicneuropathy.Whethertheobserved
growthfactordeﬁcienciesareduetodecreasedsynthesis,or
functional, e.g. an inability to bind to their receptor, and/or
abnormalities in nerve transport and processing, remains
to be established. Although early studies in humans on the
role of neurotrophic factors as a therapy for diabetic neu-
ropathy have been unsuccessful, newer agents and the pos-
sibilities uncovered by further studies should fuel clinical
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trials for several generations. It seems reasonable to antici-
pate that neurotrophic factor therapy, speciﬁcally targeted
at different nerve ﬁber populations, might enter the thera-
peutic armamentarium.
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INTRODUCTION
One of the most insidious complications of diabetes is pe-
ripheralneuropathy.Diabeticneuropathycommonlypresentsas
a small ﬁber sensory neuropathy exhibiting the typical “stock-
ingandglove”distribution.Itisthemajorcauseofamputations
in the United States, accounting for 50% to 70% of all nontrau-
matic amputations, and diabetic neuropathy accounts for more
hospitalizationsthanallotherdiabeticcomplicationscombined
(Caputo et al., 1994; Greene et al., 1992; Vinik et al., 1995a).
Thus,discoveryofaneffectivetreatmentwouldbeasigniﬁcant
boon to the care of diabetes patients.
The heterogeneity of diabetic neuropathy, with involve-
ment of large, myelinated ﬁbers that provide proprioception,
touch/pressure perception, and motor innervation, as well as
small, thinly or nonmyelinated ﬁbers providing temperature
and pain perception along with autonomic function, suggests
multiple factors in pathogenesis. The most common pathol-
ogy in both the nerves serving the periphery and in the skin
itself is a loss of nerve ﬁbers. Efforts to determine the patho-
genetic mechanisms leading to peripheral nerve dysfunction in
diabeteshasprovenquitecontroversial.Thereisgoodevidence
for several mechanisms playing a key role leading to neuronal
loss in diabetes, including: (1) metabolic disruption resulting
fromchronichyperglycemia,includingincreasedsorbitolpath-
way involvement and accumulation of advanced glycation end
products (AGEs); (2) altered vascular function leading to loss
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of nutritive support for peripheral nerve ﬁbers; (3) altered neu-
rotrophic/growth factor availability (some aspects addressed
here); (4) autoimmune processes leading to disrupted neuronal
function; (5) oxidative stress causing neuronal loss and dys-
function.Itisclearfromthe10-yearDiabetesControlandCom-
plicationsTrialsthathyperglycemiaisanimportantcomponent
drivingneuronalloss(DCCTResearchGroup,1993);however,
it seems likely that each of these mechanisms can contribute to
the degeneration of peripheral nerve function in any given pa-
tient. Determination of the mechanisms active in a particular
patient might provide better insight into the appropriate means
of treatment of the syndrome. This range of pathologies con-
tributing to diabetic neuropathy in patients might also help ex-
plain the difﬁculties in translating mechanisms and treatments
discovered in animal models to the human condition.
Early in the development of diabetic neuropathy, there ap-
pears to be an attempt at axonal regeneration, remyelination,
and synaptogenesis, possibly mediated by growth factors, that
ultimately fails to restore function. This failure is accompanied
by an enhanced rate of programmed cell death, or apoptosis.
Further supporting a role for disruption of normal growth fac-
tor function are studies showing that many of the neuronal ab-
normalities seen in diabetes can be duplicated by experimental
depletion of speciﬁc growth factors, their receptors, or their
binding proteins. It has been reported that there is a reduction
in speciﬁc growth factors in animal models of diabetes as well
as in humans, some of which are reviewed in this issue. These
reductions may be due to the associated metabolic abnormal-
ities or they may be independent of glycemic status. Many of
these factors are directly acting to maintain the health of neu-
rons,byconferringtheabilitytoresistapoptosisandpromoting
regeneration. The best studied of these factors is nerve growth
factor(NGF).NGFispartofafamilyofpeptidesknowntoexert
neurotrophic effects. It seems clear that there is a reduction of
NGFindiabetes,withevidencefordeﬁcienciesintheotherneu-
rotrophins, as well as in neurotransmitters such as substance P
(SP)andcalcitoningene–relatedpeptide(CGRP).Theselosses
can all contribute to clinical perturbations in small ﬁber func-
tion. The clinical syndrome can also be generated by selective
deletion of low-afﬁnity NGF receptors in genetically altered
transgenic animals. Clinical trials with NGF have proven dis-
appointing, but there remain questions regarding the design of
the studies. We believe that NGF still hold promise for treating
sensory and autonomic neuropathies.
In summary, there is strong support for the hypothesis that
reduced levels or activity of NGF play a signiﬁcant role in the
pathogenesisofdiabeticneuropathy.Whetherthesedeﬁciencies
are a result of lower systemic levels, an inability to activate
appropriate receptors, or abnormalities in postreceptor activity
remains to be determined. Although studies of NGF in animal
models suggest a signiﬁcant role, clinical studies have been
unsuccessful. Careful analysis of the problems with these early
clinicaltrialsmayleadtoabetterunderstandingoftheutilityof
NGF in treating diabetic neuropathy. We anticipate that NGF
will remain a viable approach in seeking therapies for diabetic
neuropathy.
ANIMAL MODELS USED TO STUDY
DIABETIC NEUROPATHY
There are a number of rodent models that have been em-
ployed to study the pathogenesis of diabetic neuropathy, in-
cluding models of type 2 and type 1 diabetes as well as drug-
induced diabetes. In early studies of diabetes, it was difﬁcult to
establish neuropathic changes in animal models, but with per-
sistence and modern techniques, it has been possible to look at
biochemical, electrophysiological, and morphological changes
over time and get a better appreciation for the pathogenesis
of diabetic neuropathy in all of these models. Examples of the
modelsfortype2diabetesusedinstudiesofdiabeticneuropathy
include the db/db mouse, which has a relatively severe disease
(Schmidt et al., 1995), the ob/ob mouse, used less frequently,
and the “Zucker” fatty (fa/fa) rat. Mouse models are limited
in studies of neuropathy due to size constraints of the nerves,
thus most of the data in the ﬁeld has been collected using the
larger rats, and there has been a good deal of useful data col-
lected using rat models in studies of diabetic neuropathy. In
addition, there are nutritionally induced type 2 models such
as the overfed C57Blk/6J mouse, in which physiology can be
studied. Because the prevalence of type 2 diabetes in humans
is approximately 90%, these models have proven important in
thestudiesofdiabeticcomplications.Inhumantype2diabetes,
neuropathy often precedes the diagnosis of diabetes, making it
difﬁcult to stage these patients. It is hoped that animal studies
of type 2 diabetes can lead to more meaningful details of the
progression of nerve dysfunction in these patients.
Less well studied are the models of type 1 diabetes such as
the NOD mouse (Sango et al., 1994) and the Wistar BioBreed-
ing (BB) rat (Nakhooda et al., 1977, 1978). The line includes
both diabetes-prone and diabetes-resistant strains, providing a
convenient control group. In addition, the BB/Z rat has proven
useful for studies of both types of diabetes due to genetic vari-
ants that can also serve as models for type 2 diabetes or as
controls (Pierson et al., 2003; Sima et al., 2001).
Themostcommonmodelusedfordiabeticneuropathystud-
ies is drug-induced diabetes in rats wherein a drug, usually
streptozotocin (STZ), which speciﬁcally destroys β cells, is
given to the animals. STZ can be given neonatally, resulting in
a syndrome mimicking type 2 diabetes as the animal ages, or it
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diabetes-like syndrome. The caveat here is that although these
animals exhibit hyperglycemia and many of the changes asso-
ciatedwithdiabetes,theydonotenduresomeoftheotherphys-
iological changes associated with the development of diabetes,
such as autoimmunity or AGE accumulation. Thus, although
information can be gained on speciﬁc mechanisms related di-
rectly to hyperglycemia, the interplay of hyperglycemia with
other pathways remains elusive.
Neuropathyinthesemodelsisdetectedbyanumberofmeth-
ods. The most common marker is nerve conduction velocity;
however, this is mainly an indicator of motor nerve function,
whereas diabetic neuropathy most commonly includes sensory
deﬁcits. It should also be noted that although animals with di-
abetes develop a sensory syndrome exhibiting both allodynia
and thermal hyperalgesia, this is not the case in humans. The
differences may explain problematic results with various forms
of treatment that appear successful in animal models, yet dis-
appointing in human trials.
The use of these models in conjunction with the proposed
mechanisms of nerve destruction have led to a number of pro-
posed therapies for diabetes patients with neuropathy. To date,
most have proven disappointing in clinical trials. However, the
most promising remain the growth factors, and of these the
prospects for neurotrophins are still bright.
NGF
NGF was ﬁrst described in the 1950s by Levi-Montalcini
(Levi-Montalcini and Booker, 1960; Levi-Montalcini and
Hamburger, 1951) and is the most thoroughly studied of the
neurotrophins.Numerousearlystudiesshowedthedependence
of neural crest-derived cells, sympathetic neurons, and dorsal
root ganglion (DRG) sensory neurons on NGF for develop-
ment. More recent studies have demonstrated that sympathetic
and DRG neurons are also dependent on NGF for maintenance
(Calcutt et al., 1990) and survival (Rich et al., 1987). These
populations are commonly affected in diabetic neuropathy.
Followingsciaticnervesectioninnormaladultrats,asignif-
icant number of the axotomized neurons in the involved DRGs
die (Calcutt et al., 1990; Himes and Tessler, 1989; Melville
et al., 1989). This cell loss can be completely eliminated by the
application of exogenous NGF to the cut proximal end of the
nerve (Rich et al., 1987). Moreover, those DRG neurons that
do not die following sciatic nerve section (Rich et al., 1987) or
in vivo NGF depletion (Calcutt et al., 1990) exhibit signiﬁcant
atrophy of their cell bodies and axons. This atrophy is at least
partially reversed by the application of exogenous NGF (Rich
et al., 1987).
NGF is also an important regulator of SP synthesis in adult
DRG neurons (Lindsay and Harmar, 1989; Schwartz et al.,
1982). SP is found in the sympathetic nervous system as well
as in a subpopulation of DRG neurons. It has been implicated
in diverse and widespread activities, including vasodilatation,
gut motility, and nociception, all of which are perturbed in dia-
betic neuropathy. Lindsay and Harmar (1989) have shown that
NGF is involved in the regulation of mRNAs that encode the
precursor molecules of SP and CGRP. In vitro NGF depriva-
tion caused cultured adult DRG neurons to down-regulate SP
and CGRP precursor molecules mRNAs (Lindsay and Harmar,
1989). Moreover, when adult rats were immunized against
mouse NGF, a procedure that caused an autoimmune deple-
tion of NGF, SP levels were reduced in the DRG, spinal cord,
andskinbyapproximately65%(Schwartzetal.,1982).Calcutt
andcolleagues(1990)concludedthatinSTZ-diabeticrats,ase-
lective down-regulation of SP precursor gene expression was
due to a decline in retrogradely transported NGF reaching the
ganglia, which in turn could explain the reduction in SP syn-
thesis and transport found in diabetic rats. It remains to be
established, however, whether the reduction in SP is pertinent
to the symptom complex of neuropathy.
A number of functional disturbances are found in the
dermal microvasculature of diabetic subjects. These include
(1) decreased microvascular blood ﬂow; (2) increased vascular
resistance, decreased tissue Po2; and (3) altered vascular per-
meabilitycharacteristics,suchaslossoftheanionicchargebar-
rier and decreased charge selectivity. Decreased microvascular
blood ﬂow and increased vascular resistance in diabetes could
result from alterations in dermal neurovascular function, such
as impaired dilator responses to SP and CGRP and reactivity
to nociceptive stimulation. Diabetes also disrupts vasomotion,
the rhythmic contraction exhibited by arterioles and small ar-
teries (Benbow et al., 1995; Stansberry et al., 1996). Unmyeli-
nated C-ﬁbers, which constitute the central reﬂex pathway, are
assumed to be damaged in diabetic neuropathy, contributing to
abnormalitiesincutaneousbloodﬂow(Stansberryetal.,1999).
TheseneuronsaredependentonNGFfortheirintegrityandsur-
vival (Rich et al., 1987; Vinik et al., 1995b). The effect of NGF
depletion may be mediated through down-regulation of neuro-
ﬁlament gene expression or RNAs that encode the precursor
molecule of SP or CGRP, both of which are NGF dependent
and down-regulated in diabetes (Vinik et al., 1995b).
The major neurotrophin considered here is NGF, although
the family, related both structurally and functionally, is much
larger, and includes neurotrophin-3, -4, and -5 (NT-3, NT-4,
and NT-5), glial-derived neurotrophic factor (GDNF), brain-
derived neurotrophic factor (BDNF), and ciliary neurotrophic
factor (CNTF). These proteins have diverse actions on dis-
tinct populations of developing neurons (Barde et al., 1982;
Hallbook et al., 1991; Hohn et al., 1990; Jones and Reichardt,
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growth factors with direct effects on neurons include insulin,
insulin-like growth factors (IGFs), laminin and saposins, cy-
tokines and other growth factor–releasing agents. The concept
of neurotrophins, with NGF as the prime example, has led to
studies showing their synthesis in target tissues, with delivery
to the affected neuron where the signal is delivered through
retrograde transport up the axon to exert the trophic and sur-
vival effects (Merhi et al., 1998). The interaction of neurons
with the growth factors released from target tissues continues
throughout life to promote the functioning, maintenance, and
survivalofbothelements.Thereisneuronaldependenceontar-
get cells for neurotrophic factors. In the neuronal soma, these
factors regulate gene expression and protein synthesis. In turn,
thetargettissuesaredependentoninnervationbythedependent
neurons to maintain tissue structure and function.
NEUROTROPHIN RECEPTORS
Neurotrophinsbindtwoclassesofreceptors:tyrosinerecep-
torkinasesortrks(trkA,trkB,trkC)andalow-afﬁnityreceptor,
“p75” (Barbacid, 1993; Chao, 1992; Glass and Yancopoulos,
1993; Meakin and Shooter, 1992). Functionally, the trks are
responsible for high-afﬁnity neurotrophin binding, leading to
signal transduction, and largely mediate the biological actions
of neurotrophins. In contrast, p75 (a 75-kDa glycoprotein) was
originally identiﬁed as a low-afﬁnity receptor for NGF. It was
initially thought only to participate in forming the functional
NGF receptor and to alter the binding afﬁnity of trk A for NGF
(Barbacid, 1993; Chao, 1992; Glass and Yancopoulos, 1993;
Meakin and Shooter, 1992). Subsequent studies have shown
thatp75iswidelyexpressedbynon-neuronalperipheraltissues
such as Schwann cells and increases following nerve injury. In
addition, p75 has been shown to act as a modiﬁer for trk B and
trk C activity as well as trk A. NGF activity is speciﬁcally asso-
ciated with activation of p75 and/or trk A, with resultant effects
onsmallsensoryandautonomicnerveﬁbers.Largenerveﬁbers,
in contrast, are dependent on the activity of trk C mediation of
NT-3 signaling, whereas BDNF, NT-4, and NT-5 exert their
effects on medium-sized ﬁbers through the trk B high-afﬁnity
receptor.
Knockout of the p75 locus in transgenic mice was found
to result in loss of small sensory ganglia, with decreased pain
sensitivity and cutaneous innervation (Kuo-Fen et al., 1994).
Sympathetic innervation of sympathetic chain ganglia (SCG)
targeting the iris and salivary glands was not affected (Kuo-Fen
etal.,1994).However,strikingabnormalitiesinthepinealgland
and the sweat glands were found. A null mutation of p75 also
caused a decrease in tyrosine hydroxylase in the pineal and
the footpad, which was accompanied by a reduction in pain
and impaired sweating. Furthermore, the neuronal defect in
p75 mutants was not due to direct effects on the target organ,
but rather was due to a failure of organ development. It is not
known how p75 receptor expression supports axonal growth,
but it might guide developing axons or facilitate the actions
of the neurotrophins at the target level. Recent studies have
indicated that p75 might bind with higher afﬁnity to proteolytic
fragments from the precursor of NGF, and it is these fragments
thatconferpro-orantiapoptoticactivityonp75signaling(Chao
and Bothwell, 2002). Alternatively, it has been suggested that
p75preferentiallybindsprepro-NGFinlargeandmediumnerve
ﬁbers, whereas mature NGF signals are targeted to small ﬁbers
(Yiangou et al., 2002). An imbalance between NGF and its
precursor form could result in functional deﬁcit in the targeted
neuron population.
Transgenic studies have shown that in development trk A
receptor mediates neuronal survival by blocking apoptotic p75
signals (Majdan et al., 2001), emphasizing the importance of
p75 interaction with trk neurotrophin receptors. Alternatively,
it has been demonstrated that there is a reduction in expression
of p75 in the autonomic ganglia of STZ-diabetic rats (Schmidt
et al., 2000), reducing NGF signaling into the neurons. Re-
gardless of mechanism, it is apparent that the low-afﬁnity neu-
rotrophin receptor is essential to the integrity of small nerve
ﬁbers involved in pain, warm thermal perception, and sweating
andassuch,constituteanimportanttargetforcorrectivetherapy
in diabetic neuropathy.
Contrasting with the role of the low-afﬁnity receptor for
neurotrophins in sensory and autonomic functions, it seems
that the high-afﬁnity trks may subserve motor and coordinating
functions. Klein and colleagues (1994) examined the role of
the trk C gene, which is expressed throughout the mammalian
nervous system and encodes a series of protein kinase isoforms
that serve as receptors for NT-3 (Barbacid, 1993; Emfors et al.,
1992;Lamballeetal.,1991,1993,1994;Tessarolloetal.,1993;
Tsoulfas et al., 1993). One of these isoforms, gp145trkC/trk C
K1, mediates the trophic properties of NT-3 in cultured cells.
ThehomozygoustrkCmutantmiceappearednormalatbirthbut
they grow poorly and most of them die soon after birth. Those
animals that survived demonstrated motor deﬁcits and develop
athetotic movements. The trk C mutants do take nourishment
and respond to painful stimuli in their whisker pads.
IncontrasttomicethatlacktrkC,micedefectiveintrkBre-
ceptors (Klein et al., 1993) lose pain perception as do mice that
lacktrkA.Smeyneandcolleagues(1994)studiedtheroleoftrks
invivo,byablatingthegeneinembryonicstemcellsbyhomolo-
gousrecombination.MicelackingtrkCwerefoundtohavease-
vere sensory and sympathetic neuropathy and most died within
1 month of birth. They were found to have extensive neuronal
loss in the trigeminal, sympathetic, and dorsal root ganglia, as
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tothehippocampusandcortex.NGFinducesneuronoutgrowth
and promotes survival of embryonic sensory and sympathetic
neurons in culture, and decreases the extent of naturally occur-
ring cell death in developing sympathetic ganglia and protects
cholinergic neurons of the basal forebrain, putamen, and cau-
date (Bradshaw et al., 1993; Dreyfus, 1989; Levi-Montalcini,
1987). Behaviorally, the animals show reduced sensitivity to
vibration and painful stimuli and have myotic pupils and pto-
sis. Therefore, these ﬁndings were thought to demonstrate that
trk A is the primary mediator of the trophic actions of NGF
in vivo, at least for certain sensory pathways (Bradshaw et al.,
1993;Dreyfus,1989;Levi-Montalcini,1987).Hencethesignal-
ing pathway for neurotrophins via their high-afﬁnity receptors
plays a crucial role in the development of both the peripheral
and central nervous systems.
Howtarget-derivedneurotrophinscansendtheirsignalback
to a distal cell body through what can be a very long axon
has been a question of increased study. Whether these sig-
nals are transduced locally at the cell membrane (MacInnis
and Campenot, 2002) or require a signaling endosome contain-
ing both NGF and trk A (Howe et al., 2001), or likely some
combination of the two, has not yet been ﬁrmly established.
However,signalingfromaninternalizedvesiclewouldhelpex-
plain the apparent importance of retrograde transport of NGF
in promoting neuronal survival.
DIABETIC NEUROPATHY
Diabetic neuropathy comprises a number of different syn-
dromeswitharangeofclinicalmanifestations.Themaingroups
of neurological disturbance in diabetes include: (1) subclinical
neuropathy established by abnormalities in electrodiagnostic
and quanitative sensory testing; (2) diffuse clinical neuropathy
with distal symmetric sensorimotor and autonomic syndromes;
and(3)focalsyndromes.Indiabeticneuropathy,dysfunctionin
almost every segment of the somatic peripheral and autonomic
nervous systems can be seen.
The different subcategories in diabetic neuropathy are dis-
tinguishedbytheirpathophysiologic,therapeutic,andprognos-
ticcharacteristics.Thedamagecaninﬂuencelargeﬁbers,small
ﬁbers,orboth.Smallnerveﬁberinvolvementoftenoccursearly
and may be present before objective signs or electrophysiolog-
ical evidence of large ﬁber deﬁcits. Small ﬁber loss is seen ﬁrst
in the lower limbs as pain and hyperalgesia, followed by loss of
thermalsensitivity,andreducedlighttouchandpinpricksensa-
tion.Areductionofproteingeneproduct9.5(PGP9.5),SP,and
CGRP in sensory neurons has been demonstrated in diabetes
(Lindbergeretal.,1989).PGP9.5isaubiquitinhydrolasefound
inthecytoplasmofallnerveﬁbers.Studiesoverthelast10years
have shown a loss of epidermal nerve ﬁbers that stain positive
forPGP9.5invariousformsofsmallﬁberneuropathy(Holland
et al., 1997). NGF is responsible for the survival and mainte-
nanceofthesecutaneousﬁbers(Ishiietal.,1994).Thereduction
of NGF may be a result of down-regulation of neuroﬁlament
gene expression or of the precursor molecule of SP or CGRP,
which are both down-regulated in diabetes (Ishii et al., 1994).
Patientswiththemostcommonpresentationofdiabeticneu-
ropathy, distal symmetric polyneuropathy (DSPN), exhibit a
“mixed”neuropathyinvolvingbothlargeandsmallnerveﬁbers.
WithDSPN,almostallpatientspresentwitha“gloveandstock-
ing”sensoryloss.Largeﬁberdysfunctionmayincludeanycom-
binationofmotorand/orsensorynerves.Largeﬁberlosscanbe
seenasreducedvibrationperception(oftentheﬁrstsignofneu-
ropathy), or loss of position sense, weakness, muscle wasting,
ordepressedtendonreﬂexes.Wehavepreviouslyillustratedthe
relationshipofdifferentnerveﬁbertypes,themodalitiesserved,
and the neurotrophins targeting them (Figure 1) (Vinik et al.,
2003).
Diabetic neuropathy is characteristically described histo-
pathologically with axonal degeneration, demyelination,
and atrophy, in association with failed axonal regeneration,
remyelination, and synaptogenesis (Calcutt et al., 1990). In
recent years, there has been greater attention paid to the factors
in diabetic neuropathy that may enhance nerve regeneration
and protect nerves from programmed cell death. Because
neurotrophins can promote the survival, maintenance, and
regeneration of neurons affected in diabetes, it is likely that
they play central roles in the alterations of nerve morphology
and function resulting from diabetes. Supporting this notion
is the amount of data showing nerve deﬁcits as a result of
removal of neurotrophins by axotomy, by depletion with
experimental induction by induced autoimmunity, or failure of
delivery or transport through genetic manipulation. Transgenic
studies wherein the neurotrophin receptors are eliminated
have conﬁrmed and reﬁned our appreciation of the different
activities and afﬁnities for the receptors based on neurotrophin
speciﬁcities. Therefore, promotion of neurotrophin action
may prove capable of preventing or reversing the changes in
diabetic neuropathy. Our concepts of the role of neurotrophins
andtheirrolesindiabeticneuropathyareillustratedinFigure2.
NGF IN DIABETES
Data suggest that a decline in NGF synthesis in diabetes has
a role in diabetic neuropathy. NGF levels in STZ-induced dia-
betic rats are dramatically reduced in the superior cervical gan-
glion, an NGF-dependent population of neurons (Steinbacher-
BC and Nadelhaft 1998). Hellweg and colleagues (1991) have
shown retrograde transport of NGF in the sciatic nerve to be re-
ducedinSTZ-induceddiabeticrats.DecreasedretrogradeNGF276 G. PITTENGER AND A. VINIK
FIGURE 1
Schematic illustration of the peripheral nervous system, nerve ﬁber types, and the potential growth factors responsible for the
integrity of the different ﬁber types (from Vinik et al., 2003).
transport in axons of the STZ-induced diabetic rat ileal mesen-
teric nerves has also been reported (Himes and Tessler, 1989),
precedingthedevelopmentoffrankdistalaxonopathy.Itseems
reasonable to suspect that perturbations in NGF availability in
some way contributes to the development of diabetic neuropa-
FIGURE 2
An illustration of the pathways to nerve damage in diabetes, the type of nerve ﬁber involved, and the potential for neuroprotection
by growth factors, integrins, and cytokines (adapted from Vinik et al., 2003).
thy.Perturbationsofpainsensationarecharacteristicofdiabetic
neuropathy and the levels of SP, a nociceptive transmitter, are
reduced in diabetic rats in parallel with increased tolerance to
pain (Garrett et al., 1995). In addition, the amount of antero-
gradely transported SP was reduced in STZ-induced diabeticNGF AND DIABETIC NEUROPATHY 277
rats (Garrett et al., 1995; Robinson et al., 1987). Treatment
with the aldose reductase inhibitor sorbinil, or its combination
with gangliosides, increases the amount of SP transported in
sciatic nerves of diabetic rats and is accompanied by pain hy-
persensitivity (Garrett et al., 1995; Robinson et al., 1987). This
suggests that by increasing SP production and transport, NGF
may restore disordered pain perception toward normal in dia-
betic neuropathy.
Innormalskin,NGFisproducedbybasalkeratinocytes,and
acts via its high-afﬁnity receptor (trk A) on nociceptor nerve
ﬁbers to increase their sensitivity, particularly in inﬂammation
(Facer et al., 2000). In vitro studies show that keratinocytes ex-
press both NGF and its high-afﬁnity receptor, trk A, and that
NGF may increase keratinocyte proliferation and its own ex-
pression via an autocrine loop (Terenghi et al., 1997). NGF
is reduced in epidermal keratinocytes in human diabetic skin,
and this decrease has been related to dysfunction of cutaneous
sensory ﬁbers. These data can be interpreted to suggest that
abnormal availability of target-derived NGF may be responsi-
bleinpartforearlysmall-ﬁberneuropathy(Anandetal.,1996).
RecentdatasuggestthatprecursorformsofNGFthatbindmore
speciﬁcally to p75 are reduced in skin from both humans and
rats with diabetic neuropathy (Yiangou et al., 2002). Thus, the
mechanism of target-derived NGF dysfunction at the level of
the epidermis that leads to peripheral diabetic neuropathy is
slowly being elucidated.
Alterations in endogenous blood concentrations of NGF
may be associated with hyperglycemia and/or diabetes, and
may be relevant to the development of neuropathy. Hellweg
and colleagues (1991) found that endogenous NGF concentra-
tions were low in STZ-diabetic rats and could be restored by
allogenic islet transplantation. Similarly, NGF serum concen-
trationswerediminishedandtissuecontentwasdecreasedinthe
submaxillaryglandandsciaticnerveofmicemadediabeticwith
STZ compared with matched controls (Ordo˜ nez et al., 1994).
Low levels of NGF could be due to either decreased production
or transport of NGF in diabetes or both, possibly as a result
of glucose-induced oxidative stress (Fernyhough et al., 1998;
Hounsometal.,2001;Stevensetal.,2000;Vincentetal.,2002).
Inaddition,autoimmunitymayplayaroleintheNGFdeﬁciency
in diabetes by mechanisms related to immune neutralization of
availableNGF.Therearestructuralandbiochemicalsimilarities
betweenNGFandtheinsulinfamilyofpeptides,andithasbeen
suggested that antibodies to insulin may cross-react with NGF
and contribute to an effective reduction in NGF available to
nerves, thereby contributing to the development of neuropathy
(Bennett, 1983). Because NGF-receptor signaling selectively
induces tyrosine hydroxylase, and dopamine beta hydroxylase
is necessary for the survival of sympathetic nerve ﬁbers (Barde
et al., 1982) and is required for the expression of SP and CGRP
in adult sensory neurons, it is apparent that immune neutraliza-
tion of NGF could generate a clinical syndrome not unlike that
found in diabetic neuropathy (Anand et al., 1991).
NGF IN TREATMENT OF DIABETIC
NEUROPATHY
It has now been shown that NGF treatment ameliorates di-
abetic sensory neuropathy in animals. Apfel and colleagues
(1994)administeredNGFtoratsat3µg/gor5µg/gthreetimes
weekly, starting 1 week after STZ administration. Reduction in
pain sensation was prevented, as was the fall in CGRP in DRG
intheuntreateddiabeticanimals.NGFalsopreventedreduction
in levels of another peptide, SP, in sensory ganglia of diabetic
animals. NGF did not, however, prevent the deﬁcit in tibial
motor conduction in diabetic rats, suggesting that NGF may
be a useful adjunct for the treatment of diabetic sensory and
autonomic, but not motor, neuropathy (Williams et al., 1993).
Diemelandcolleagues(1994)havealsoshownthatratswith
STZ-induced diabetes are depleted of both SP and CGRP pep-
tides in the sciatic nerve, as well as having depletion of CGRP
and gamma-preprotachykinin A mRNA in the fourth and ﬁfth
lumbarDRG.TreatmentofratswithNGFpreventedthedeﬁcits
in the levels of CGRP and gamma-preprotachykinin mRNA
as well as normalized the levels of CGRP and SP peptides in
lumbar DRGs. The effects in the diabetic animals were much
more marked than those in the nondiabetic animals. There was
no response to BDNF. The demonstration that in vivo sys-
temic administration of NGF can reverse the deﬁcits in SP
and CGRP in peripheral sensory neurons of diabetic rats lends
support to the notion that deﬁcient expression or response to
NGF may be important for development of diabetic neuropa-
thy. The authors further suggest that systemic administration of
NGF may be of value in treating the sensory forms of diabetic
neuropathy.
Two randomized, placebo-controlled clinical trials of re-
combinant human NGF (rhNGF) administered to patients with
polyneuropathy were initiated. In a phase II clinical trial of
rhNGF in 250 patients with diabetic polyneuropathy, improve-
ments in signs and symptoms were seen after treatment with
either 0.1 or 0.3 µg/kg rhNGF, subcutaneously, three times a
week for 6 months. A second phase II trial in 270 patients with
human immunodeﬁciency virus (HIV)-associated sensory neu-
ropathy demonstrated signiﬁcant improvements in neuropathic
pain and sensitivity to pinprick, following 18 weeks of treat-
ment with either 0.1 or 0.3 µg/kg rhNGF twice a week (Apfel
et al., 1998). In addition, both studies suggested that admin-
istration of rhNGF was well tolerated with the exception of
self-limited injection site hyperalgesia and other pain-related
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250 patients with diabetic neuropathy, NGF improved a com-
posite score, which included measures of small ﬁber function,
warmthermalthreshold,coolingdetectionthreshold,andnerve
impairment scores in the lower limb (Vinik, 1999). As a re-
sult of this success, a 48-week randomized, placebo-controlled
phase III study of rhNGF in a dose of 0.1 µg/kg (n = 504) or
placebo(n=515)subcutaneously3times/weekwascarriedout.
The primary outcome measure was change in baseline on the
Neuropathy Impairment score for the lower limbs. Secondary
outcomemeasuresalsoincludedquantitativesensorytestusing
the Case IV device, Neuropathy Symptom and Change score,
and the patient beneﬁt questionnaire. Nerve conduction studies
werealsoperformedandincidenceoffootulcerswasobserved.
Eighty-threepercentofpatientscompletedthestudy,compared
with 90% of the placebo group. rhNGF induced signiﬁcant in-
jection site hyperalgesia, which made true blinding difﬁcult,
and there was no signiﬁcant difference in the primary outcome
(P = .25). Furthermore rhNGF did not exhibit signiﬁcant im-
provement in the secondary end points. However, there were
signiﬁcant, albeit modest, improvements in the global assess-
ment scores (P <.03) and 2 of 32 comparisons in improve-
ment in global symptoms (P =.05 for leg pain; P =.003 for
6 months’ symptoms in the hands and feet). The reasons for
these poor results compared with the phase II study are not
entirely clear. We noted a surprising lack of progression in neu-
ropathy in the placebo-treated group, suggesting that modern
management of patients with diabetes has resulted in a change
in the natural history of the condition, dictating a more robust
end point and possibly longer-duration studies. If the ability
of rhNGF is not robust and if all it can do is prevent the pro-
gression of neuropathy, it would not be possible to show an
effect in a 1-year trial. Among the possible other reasons for
the conﬂicting data between the phase II (Vinik, 1999) and this
phase III study (Periquet et al., 1999) were possible differences
in dose, concentration, and the preparation of NGF, choice of
end points, measurements of neuropathy (no direct estimation
of small ﬁber changes in the skin were made), and patient pop-
ulations. Further, it is uncertain whether systemic NGF can
signiﬁcantly reverse microvascular defects that may contribute
to neuronal loss, although it has been shown that NGF im-
proves physiological control of microvascular perfusion (Ben-
nett et al., 1998b). Whether this is a direct effect of NGF on
microvessels or a result of improved neural function is not
certain.
The end point for these studies employed a composite scale
(Apfel et al., 2001) that may have masked changes speciﬁc
to the nerve ﬁbers targeted by NGF. Using sophisticated mea-
sures of cognitive function, e.g., thermal perception, requires
highly skilled and trained personnel not available when ad-
vancing from a few centers in the phase II (successful) to many
centers (unsuccessful) in the phase III study. With the recent
developments of improved methods for identifying C ﬁbers
in skin by immunohistochemistry and quantiﬁcation of nerve
ﬁberdensityusingthepan-neuronalmarkerPGP9.5(Herrmann
etal.,1999;Langeretal.,1995;SimaandSugimoto,1999),and
functional tests of C-ﬁber integrity including measures of skin
blood ﬂow (Cardillo et al., 1999; Stansberry et al., 1999), it
might be possible to overcome the end point limitations in-
herent in the study design and rescue NGF from a premature
demise as a therapeutic agent in diabetic neuropathy. Further,
recent reports have demonstrated the profound effects of both
microvascular dysfunction and oxidative and nitrative stress in
the pathogenesis of diabetic neuropathy (Ceriello et al., 2001;
Hoeldtkeetal.,2002;Stuhlingeretal.,2002;Viniketal.,2001;
Zavaronietal.,2000).Itmaybethatneurotrophinsalonecannot
overcome the damage caused by these mechanisms to periph-
eralnerveﬁbers,thusrequiringmultimodaltreatmenttoachieve
the desired recovery.
NGF/GROWTH FACTOR INTERACTION
NGF may also interact with other neurotrophic agents to
modify neuronal survival. An example of this is the effect of
IGF-II on NGF receptors. In serum-free medium, NGF recep-
tor binding diminishes and NGF fails to have a physiologi-
cal effect on the neuron as a result. Addition of IGF-II to this
serum-free medium can induce NGF receptor binding and thus
restore NGF function in neurons. Although IGFs and NGF
can work together to maintain normal nerve integrity, there
appears to be a separate role for each of these neurotrophins
in neurite outgrowth. Antisera to NGF, for example, do not
block the effects of IGF on tubulin synthesis and differen-
tiation. Aside from the direct effects insulin and the IGFs
have on neurite outgrowth and regeneration, it is possible
that IGFs exert a major action through modulation of NGF
activity.
It has been known for some time that insulin stimulates
many anabolic processes in its target cells. Recently, this has
been stated in a more uniﬁed concept designated as the pleio-
typic response. The processes that have been found to be under
pleiotypiccontrolareuridineuptake,RNAsynthesis,polysome
formation, protein synthesis, protein degradation, and glucose
utilization (Vinik et al., 1995b). The response to insulin closely
parallels that of sensitive neurons to NGF in vitro. Sensory
ganglia respond to NGF with an increase in uridine uptake,
synthesis of all classes of RNA, protein synthesis, and glu-
cose utilization. Also, NGF increases lipid synthesis, an aspect
that might be related to a pleiotypic growth response (Watkins,
1995). The striking similarity between the structure of NGF
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proinsulin. This may be an example of converging evolution
withformationofanewfunctionfromapreexistingproteinand
maybecomparedwiththeevolutionofalpha-lactalbuminfrom
lysozymeandthedevelopmentofseveralpancreaticserinepro-
teases with varying speciﬁcity from a primitive precursor (Hill
et al., 1968). Thus, NGF might best be considered among the
growth factors as occupying a position intermediate between
proteinhormonesandinducers.Frazierandcolleagues(Frazier
et al., 1972) have developed a model in which they suggest
that an ancestral proinsulin comprised of B, C, and A chains
ﬁnally gives rise to a fragment of 50 residues, which comprises
the insulin A and B chains, undergoes contiguous reduplica-
tion, deletion, and modiﬁcation, with ﬁnal translation into an
NGF with 118 residues, comprised of B, C, A, and B chains.
The stimulating pathways or pleiotropic actions of insulin and
NGF may include two distinct but related pathways involving
stimulation of both serine/threonine kinases and phosphatases
(Saltiel, 1990; Saltiel and Cuatrecasas, 1988). The sequence of
eventsfollowingtheinitialinteractionwithNGFandinsulinand
the receptor bear remarkable similarities. The NGF receptors
bear considerable structural homology with the insulin recep-
tor.Withinthetrkdomain,allofthetrkproteinsshowed40%to
50% sequence identity with the insulin receptor and over 80%
sequence similarity. The similarities between NGF and insulin
instructure,cellularactions,earlysignalingevents,andreceptor
structure/function have led to renewed interest in the biology
of newly discovered and previously recognized neurotrophic
factors. It is indeed for this reason that we are interested in the
overlapbetweentheactionsandmechanismsofinsulinandneu-
rotrophinsandtheirinvolvementinthepathogenesisofdiabetic
polyneuropathy.
NGF AND APOPTOSIS
Recent studies indicate that apoptosis may be a mechanism
whereby diabetes induces nerve damage and wherein diabetes
opposes the antiapoptotic mechanisms that normally protect
nerves. However, this remains to be demonstrated in human
diabetes. It is of interest that NGF can rescue neuronal cells
from apoptosis (Jensen et al., 1992; Rabizadeh et al., 1993).
Apoptosis is regulated by many extrinsic and intrinsic cellu-
lar signals, and the threshold of apoptotic cell death is also
dynamically regulated by multiple inducers and inhibitors of
gene products (Steller, 1995). Several apoptosis-related onco-
gene products are also expressed and regulated by extracellular
signals in neurons. Bcl-2, a cell-death suppressor, is found in
themitochondrialmembrane,thenucleus,andtheendoplasmic
reticulum. A high level of expression of bcl-2 in sympathetic
neurons prevented cell death induced by deprivation of NGF
(Garcia et al., 1992).
Fas (APO-1, CD95) is a type I cell-surface receptor with
a molecular weight of 35 to 40 kDa, dependent on the source
species, belonging to the tumor necrosis factor (TNF)/NGF re-
ceptor superfamily. Fas is expressed in many cell lines, but
the largest body of research shows that Fas mediates apoptosis
in susceptible T-lymphocyte target cells (Weller et al., 1994).
Fas-mediated apoptosis may be antibody dependent. When Fas
ligand(FasL)oranti-FasantibodiesbindtotheFasreceptor,the
target cell undergoes apoptosis. The apoptotic signal through
Fasrequiresthecross-linkingandtrimerizationofFasreceptors
(Peitsch and Tschopp, 1995). The trimerized Fas complex can
then be activated by antibody action, resulting in the transduc-
tion of the signal for induction of apoptosis. Polymerization of
Fas can be accomplished either with (FasL) or with antibod-
ies to Fas recognizing speciﬁc epitopes (Nagata and Golstein,
1995).Consistentwiththishypothesis,ourstudiesutilizingim-
munoﬂuorescence with N1E-115 neuroblastoma cells revealed
aclusteringofFasontheneuroblastomacellsurfaceinresponse
totype1diabeticserum(Pittengeretal.,1997),incontrasttoits
normal diffuse distribution on the cell membrane. This cluster-
ing appears to be a consequence of molecular cross-linking of
Fas by a factor in type 1 diabetic serum. According to our pre-
vious study, the cytotoxic factor is likely to be an autoantibody
(Pittenger et al., 1995). Our ﬁnding that type 1 diabetic serum
blocks the Fas cell-surface immunoﬂuorescence using a Fas-
speciﬁc antiserum suggests competition of the immunoglobu-
lin G (IgG) in type 1 diabetic serum and the rabbit anti-Fas
antibody, indicating that Fas might be one of the membrane
antigensrecognizedbyautoantibodiesintype1diabeticserum.
Cytotoxicityoftype1diabeticserummightbeenhancedbythe
expression of Fas or an increase in circulating FasL. Indeed,
Guillotetal.(2001)reportanincreaseofcirculatingFas,butnot
FasL, in patients with diabetic neuropathy, but not in diabetes
patients with retinopathy or no complications. Thus, it may be
that down-regulation of NGF as seen in diabetes may unbridle
the action of circulating Fas in peripheral nerves, speciﬁcally
linking Fas to neuronal destruction in diabetes. At this time,
there is no evidence in the literature for or against the presence
of Fas or FasL action on peripheral neurons in diabetes.
There is good evidence from studies in neuroblastoma cell
cultures for antiapoptotic signaling through the phosphatidyli-
nositol 3 -kinase signaling pathway (Jaboin et al., 2002), with
subsequent signaling through the mitogen-activated protein
(MAP) kinase/Akt cascade, resulting in neurite outgrowth
(Piiper et al., 2002). If the MAP kinase/Akt signaling sys-
tem is disrupted, as appears to be the case in diabetes, this
could compromise NGF signaling and contribute to the de-
velopment of diabetic neuropathy, in some cases even before
the metabolic effects become symptomatic. We cannot exclude
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such as glycolipids, the low-afﬁnity NGF receptor (p75), the
TNF-α receptor, or other as yet unknown regulators of apop-
tosis, may also be involved. The roles of these regulators in
apoptotic neuronal death and whether they might contribute to
thedevelopmentofdiabeticneuropathyremaintobeelucidated.
These ﬁndings support the possibility that alternate treatments
for diabetic neuropathy may include antiapoptotic maneuvers.
Another possible route of antiapoptotic action for NGF is
blockade of oxidative stress pathways. It has been shown that
NGF can serve as an antioxidant in its own right (Lieberthal
et al., 1998; Pan et al., 1997). Thus, with the reduced levels of
NGF seen in diabetes, there is a concomitant increase in per-
oxynitrites in local tissues, leading to cleavage of caspases and
activation of the apoptotic cascade (Park et al., 1998). NGF ap-
pearstoexerttheseeffectsthroughthelow-afﬁnityp75receptor
(Vincent et al., 2002) Another aspect of NGF treatment of neu-
rons is the up-regulation of the antiapoptotic cellular proteins
bcl-2 and bcl-x (Muller et al., 1997; Park et al., 1998). Thus,
there are a number of ways for neurotrophins, and NGF specif-
ically, to promote neuronal survival in the face of diabetes.
THERAPEUTIC POTENTIAL FOR NGF
As we understand the role of neurotrophins in the control
of growth initiation, proliferation of neurons, and the apoptotic
process,itbecomespossibletoconsidertheuseofneurotrophic
factors in the treatment of diabetic neuropathy. Aided by the
availability of large quantities of recombinant neurotrophic
factors, it is feasible to consider their possible place in the
management of diabetic neuropathy. The choice of the optimal
neurotrophic factor is dependent upon an awareness of the neu-
ronal population involved in the disease process and an under-
standing of the speciﬁcity of each factor for a speciﬁc neuronal
populationaffectedbythediseaseprocess.Thisemphasizesthe
need for more speciﬁc delineation of the neuronal population
involvedinthediseaseprocessaswellasthespeciﬁcsyndrome
present in a particular patient. Because both sympathetic and
DRG express receptors for NGF, it may prove efﬁcacious for
the treatment of both the small ﬁber autonomic and sensory
neuropathies. The optimum approach to mixed sensory neu-
ropathies may be the use of factors with less speciﬁcity for mo-
tor or sensory neurons. Approximately a third of primary sen-
sory neurons do not express trk receptors, and can be identiﬁed
bythebindingofthelectinIB4.Theseneuronshavebeenfound
toexpressRetmRNA,thesignaltransductioncomponentofthe
receptorforGDNF,amemberofthetransforminggrowthfactor
(TGF)-β superfamily (Bennett et al., 1998a). Ret is a common
receptor for GDNF and neurturin, and it interacts with either
of two other receptor subunits, GFRα-1 and GFRα-2. Ret re-
ceptors have been identiﬁed in small-diameter primary sensory
neurons, and colocalize with GFRα-1 and GFRα-2 subunits
(Vinik et al., 1999). Initially, GDNF was thought to support
survival of only dopaminergic neurons, but recent reports have
shown it to be a potent neurotrophic factor for many other neu-
ronal populations. GDNF prevents the slowing of conduction
velocity that normally occurs after axotomy in a population
of small-diameter DRG cells and the A ﬁber sprouting into
lamina II of the dorsal horn (Vinik et al., 1999). GDNF has a
trophic effect on motoneurons and autonomic neurons (Vinik
et al., 1999) as well as Schwann cells that implicate its diverse
role in promoting peripheral nerve regeneration.
Alternatively, new gene therapy methods are showing
promise for delivery of neurotrophins resulting in improve-
ments in diabetic neuropathy. Goss et al. (2002) have used
cytomegalovirus (CMV) immediate-early promoter for deliv-
ery of NGF into the DRG and adipose tissue and herpes sim-
plex latency active promoter 2 delivered into the footpad of
STZ-diabetic mice, and demonstrated a block of degradation
of foot sensory amplitude, a marker of the development of
neuropathy. It is of interest that delivery of NT-3 with an
adenovirus-based vector and of VEGF with a CMV promoter
both have been shown to relieve the development of neuropa-
thy in drug-induced diabetic rats and rabbits (Pradat et al.,
2001; Schratzberger et al., 2001). These studies further sup-
port the multimodal needs for reversing peripheral nerve dam-
age. Thus, although systemic administration of NGF, and neu-
rotrophins in general, may prove disappointing, gene therapy
might provide an effective mode of delivery for these powerful
agents.
By stimulating nerve growth and regeneration as well as re-
modeling, administration of growth factors that target neurons
may decrease the vulnerability to damage by the diabetic dis-
ease process. NGF has been considered for the treatment of
Alzheimer’s disease because of the loss of cholinergic neurons
in this disease and the pronounced and selective trophic action
of NGF upon cholinergic neurons (Hefti and Schneider, 1989).
Recombinant NGF has been shown to reverse experimental
cholinergic injury in animals (Goodman et al., 1953). Basic
ﬁbroblast growth factor (bFGF) and BDNF also protect cholin-
ergic cell bodies, although less well than NGF (Anderson et al.,
1988; Schwaber et al., 1991). The major brunt of diabetic neu-
ropathy is initially borne by the long parasympathetic, cholin-
ergic nerves and their neurons, suggesting that NGF alone, or
in combination with BDNF or bFGF, may have a place in the
treatment of parasympathetic neuropathy.
There is a reason to consider other prospects for growth fac-
tor therapy in diabetes. Even motoneurons may be protected
from cell death. CNTF rescues motoneurons from naturally
occurring cell death during chick embryo development and
may retard motoneuron degeneration in the adult (SendtnerNGF AND DIABETIC NEUROPATHY 281
et al., 1990). Among a variety of approaches being used to
enhance peripheral nerve regeneration is the manipulation of
Schwann cells and the use of neurotrophic factors. Such fac-
tors include NGF and the members of the neurotrophin family,
namely,BDNF,NT-3,NT-4/5,theneurokines,CNTF,leukemia
inhibitory factor (LIF), and the TGF-β family and their distant
relative, GDNF (Hayakawa et al., 1994).
Early results of treatment of toxic neuropathies with growth
factors are encouraging. The small ﬁber sensory neuropathy
induced by Taxol can be prevented by the administration of
NGF(Koningsetal.,1994).Thelargeﬁberneuropathyinduced
by the antitumor agent cisplatin with prominent proprioceptive
deﬁcits can be prevented in rodents treated with NGF (Hiraiwa
et al., 1997), which has also been shown to prevent or delay the
development of sensory neuropathy in STZ-induced diabetes.
SUMMARY
Although the mechanism of action is as yet unknown, the
currentknowledgeofgrowthfactors,andNGFspeciﬁcally,and
theirrelationshiptodiabeticneuropathysuggestsapathophysi-
ological role for reduced levels of NGF available for retrograde
transport to neuronal cell bodies. In addition, there is likely a
compromise of the p75 and trk A receptors responsible for me-
diatingNGFsignaling.Itisnowconceivablethatneuronalfunc-
tion may be compromised, and atrophy of nerves, and possibly
even cell death, may be a consequence of a reduction of overall
NGF activity in diabetic neuropathy. Whether the growth fac-
tor deﬁciency is due to decreased synthesis, an inability of the
factor to bind to its receptor, disturbances in retrograde axonal
transport, or intraneuronal processing also remains to be estab-
lished. Further studies aimed at understanding the disturbances
in expression of NGF-related genes and proteins, as well as
their receptor binding and subsequent transport from sites of
synthesis to sites of action should shed considerable light on
therelationshipbetweenNGFactivityanddiabeticneuropathy.
Other contributors to the pathogenesis of diabetic neuropathy,
suchasmicrovasculardiseaseandnitrativestress,willalsohave
to be addressed in any further attempts to use neurotrophic
factor therapy. It is unlikely that neurotrophins will succeed
as monotherapy, but their use in conjunction with agents that
combat the myriad of dysfunctions in diabetes is likely to yield
better results. Discovery of these relationships will hopefully
lead to more efﬁcacious therapies involving neurotrophins in
general and NGF speciﬁcally.
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